SV

Street Verdict

Analyst Scorecard

GLAND · NSE

Gland Pharma Limited

₹3,331.9

+1.18% (+₹39)

Prev. close

₹3,292.9

Volume

3,00,572

Delivery %

70.9%

As of

20 Nov 2026

Price history

₹3,331.9+₹473.3 (+16.56%) · 3M
18 Aug 2026 → 20 Nov 2026
2,9003,0003,1003,2003,30018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

5 analyst stances · last 90 days · one per analyst

Trackable

5 · 5 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (5)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 4 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Gland Pharma Limited

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Srinivas Sadu

Headquarters

Hyderabad

Employees

4,332

Key stats

Market cap

₹52,417.35 Cr

P/E ratio (TTM)

46.4

Dividend yield

0.63%

EPS (TTM)

₹68.47

Beta (1Y · daily vs NIFTY 50)

0.58

Beta (5Y · monthly vs NIFTY 50)

0.28

Shares float

8.94 Cr

EPS · quarter ended Jun 2026

₹19.22

Financial Performance

01 · Financials

0 Cr2500 Cr5000 Cr7500 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0255075₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

05101520₹-10%-5%0%5%16 Aug 2414 Aug 2511 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%0%100%200%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr5000 Cr10000 Cr15000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr5000 Cr10000 Cr15000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

Inventory for FY21 and FY22: from the company's own statements, which the series had none for. Cash for FY21 and FY22: from the company's own statements, which the series had none for.

08 · Profit & Loss — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹3,597.65 Cr₹4,624.65 Cr₹3,865.06 Cr₹5,834.96 Cr₹5,830.11 Cr₹6,746.98 Cr
₹2,262.84 Cr₹3,006.09 Cr₹2,754.02 Cr₹4,702.42 Cr₹4,767.45 Cr₹5,258.05 Cr
Profit before exceptional item and tax (III)= (I-II)
₹1,334.81 Cr†₹1,618.55 Cr₹1,111.04 Cr₹1,132.54 Cr†₹1,062.66 Cr₹1,488.93 Cr
₹1,334.81 Cr₹1,618.55 Cr₹1,054.58 Cr₹1,132.54 Cr₹1,062.66 Cr₹1,464.58 Cr
₹337.85 Cr₹406.89 Cr₹273.54 Cr₹360.08 Cr₹364.13 Cr₹437.26 Cr
Profit for the year (VII)=(V-VI)
₹996.96 Cr₹1,211.66 Cr₹781.04 Cr₹772.46 Cr₹698.53 Cr₹1,027.32 Cr
₹87.20 L₹45.80 L₹1.44 Cr₹7.87 Cr₹-55.39 Cr₹-430.99 Cr
Total comprehensive income for the year, net of tax (IX) = (VII+VIII)
₹996.09 Cr₹1,211.21 Cr₹779.61 Cr₹764.60 Cr₹753.91 Cr₹1,458.30 Cr
Basic, computed on the basis of profit attributable to equity holders
63.0773.81————
Diluted, computed on the basis of profit attributable to equity holders
62.9973.64————
Owners of the Company
₹996.96 Cr₹1,211.66 Cr₹781.04 Cr₹772.46 Cr₹698.53 Cr₹1,027.32 Cr
Owners of the Company
₹996.09 Cr—₹779.61 Cr₹764.60 Cr₹753.91 Cr₹1,458.30 Cr
Basic (₹)
——47.4446.9042.4062.35
Diluted (₹)
——47.4346.8942.4062.28

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY21FY22FY23FY24FY25
₹6,496.08 Cr₹7,833.62 Cr₹8,777.54 Cr₹10,661.25 Cr₹11,224.92 Cr
₹6,496.08 Cr₹7,833.62 Cr₹8,777.54 Cr₹10,661.25 Cr₹11,224.92 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

‡ The company printed this figure on a line with no label (a bare subtotal under a block). Where the lines above add up to it, it is named after them; otherwise it is shown as “Unlabelled line”. The figure is the company’s own.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹604.93 Cr₹790.77 Cr₹363.97 Cr₹996.80 Cr₹914.73 Cr₹1,031.39 Cr
₹-1,524.00 Cr₹-1,002.62 Cr₹1,208.19 Cr₹-1,756.91 Cr₹1,704.74 Cr₹137.73 Cr
₹492.46 Cr₹318.82 Cr₹1,908.90 Cr₹357.09 Cr₹2,556.21 Cr₹3,359.11 Cr
₹492.46 Cr₹318.82 Cr₹1,908.90 Cr———
Net cash (used in)/generated from financing activities (C)
——₹14.92 Cr———

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21–Mar 22(2Q)Jun 22Sep 22–Mar 24(7Q)Jun 24–Mar 26(8Q)Jun 26
Promoter58.02%58.00%57.87%57.86%51.83%51.77%
Public41.97%42.00%42.13%42.14%48.17%48.23%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Gland Pharma Limited₹51,740.80 Cr₹3,15945.85.009.9%0.03+14.7%+65.2%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

GLAND

Gland Pharma Holders Are Up 93% And Here Is What They Saw

Gland Pharma’s shares have risen about 93% year‑to‑date, reaching roughly ₹3,293 from ₹1,715 at the start of 2026. The rally follows a U.S. FDA approval for a methylprednisolone injectable, which helped lift quarterly revenue to ₹18.34 billion and improve net margin to 15.9%, prompting optimistic fair‑value estimates despite some analysts warning of capacity‑utilisation risks.

GLAND

LINK PHARMA Share Price Today Up 11%

Gland Pharma shares rose about 80% over the past twelve months, making it one of the top gainers in the BSE Healthcare index. The surge contrasts with broader market trends, as the BSE Healthcare index gained 17.8% while the BSE Sensex fell 3.2% in the same period.